182 related articles for article (PubMed ID: 24575635)
1. [Incidence of complications of antithrombotic treatment in patients with atrial fibrillation].
Novaković Anucin S; Gnip S; Canak V; Radović P; Kovacev J; Mitić G
Med Pregl; 2013; 66(11-12):470-5. PubMed ID: 24575635
[TBL] [Abstract][Full Text] [Related]
2. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
3. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
[TBL] [Abstract][Full Text] [Related]
4. Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso.
Yameogo AR; Kologo JK; Mandi G; Kabore HP; Millogo GR; Seghda AA; Samadoulougou AK; Zabsonre P
Pan Afr Med J; 2016; 24():108. PubMed ID: 27642447
[TBL] [Abstract][Full Text] [Related]
5. [Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?].
Volkmann H; Walter M; Bergmann C; Rose E; Krpciar V; Vetter S
Herzschrittmacherther Elektrophysiol; 2009 Jun; 20(2):61-9. PubMed ID: 19543788
[TBL] [Abstract][Full Text] [Related]
6. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
; Connolly SJ; Pogue J; Hart RG; Hohnloser SH; Pfeffer M; Chrolavicius S; Yusuf S
N Engl J Med; 2009 May; 360(20):2066-78. PubMed ID: 19336502
[TBL] [Abstract][Full Text] [Related]
7. [Anticoagulation in atrial fibrillation. Strategies in special situations].
Volkmann H; Walter M; Walter C; Vetter S
Clin Res Cardiol Suppl; 2011 May; 6():58-65. PubMed ID: 22528179
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of thromboembolic and hemorrhagic events in patients with atrial fibrillation under anti-vitamin K.
Ben Rejeb O; Brahim W; Ghali H; Ernez S; Mahdhaoui A; Jeridi G
Tunis Med; 2019 Mar; 97(3):432-437. PubMed ID: 31729717
[TBL] [Abstract][Full Text] [Related]
9. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
[TBL] [Abstract][Full Text] [Related]
10. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
[TBL] [Abstract][Full Text] [Related]
11. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontané; FFAACS).
Lechat P; Lardoux H; Mallet A; Sanchez P; Derumeaux G; Lecompte T; Maillard L; Mas JL; Mentre F; Pousset F; Lacomblez L; Pisica G; Solbes-Latourette S; Raynaud P; Chaumet-Riffaud P;
Cerebrovasc Dis; 2001; 12(3):245-52. PubMed ID: 11641591
[TBL] [Abstract][Full Text] [Related]
13. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
Olesen JB; Lip GY; Lindhardsen J; Lane DA; Ahlehoff O; Hansen ML; Raunsø J; Tolstrup JS; Hansen PR; Gislason GH; Torp-Pedersen C
Thromb Haemost; 2011 Oct; 106(4):739-49. PubMed ID: 21789337
[TBL] [Abstract][Full Text] [Related]
14. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
Van Der Meersch H; De Bacquer D; De Vriese AS
Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
[TBL] [Abstract][Full Text] [Related]
16. Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study.
Dinh T; Baur LH; Pisters R; Kamp O; Verheugt FW; Smeets JL; Cheriex EC; Lindeboom JE; Heesen WF; Tieleman RG; Prins MH; Crijns HJ;
Heart; 2014 Apr; 100(7):563-8. PubMed ID: 24488608
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.
Cotté FE; Benhaddi H; Duprat-Lomon I; Doble A; Marchant N; Letierce A; Huguet M
Clin Ther; 2014 Sep; 36(9):1160-8. PubMed ID: 25151574
[TBL] [Abstract][Full Text] [Related]
18. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
[TBL] [Abstract][Full Text] [Related]
19. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
Kozlowski D; Budrejko S; Raczak G; Rysz J; Banach M
Curr Pharm Des; 2013; 19(21):3816-26. PubMed ID: 23286429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
